In addition, SETD2 deficiency enhances resistance against imatinib in CML cells by upregulating novel oncogenes, such as erythroblast transformation‐specific (ETS)‐related gene (ERG) and N‐myc proto-oncogene protein (MYCN)84. Here, SETD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.